Key result
Dapagliflozin accelerated blood flow recovery and reduced limb necrosis in a hindlimb ischemia mouse model by inducing M2 macrophage polarization and stimulating angiogenesis.
Why the study?
Does dapagliflozin improve recovery from limb ischemia in a mouse model of hindlimb ischemia?
Does dapagliflozin improve recovery from limb ischemia in a mouse model of hindlimb ischemia?
Dapagliflozin promotes angiogenesis and blood flow recovery in a mouse model of hindlimb ischemia by inducing M2 macrophage polarization, suggesting potential therapeutic utility for critical limb ischemia.
Should not change limb ischemia practice; leaves open human translation of angiogenic effects.
Critical limb ischemia (CLI) is associated with a higher risk of limb amputation and cardiovascular death. Dapagliflozin has shown great potential in the treatment of cardiovascular disease. However, the effects of dapagliflozin on CLI and the underlying mechanisms have not been fully elucidated. We evaluated the effect of dapagliflozin on recovery from limb ischemia using a mouse model of hindlimb ischemia. The flow of perfusion was evaluated using a laser Doppler system. Tissue response was assessed by analyzing capillary density, arterial density, and the degree of fibrosis in the gastrocnemius muscle. Immunofluorescence and Western blot were used to detect the expression of macrophage polarization markers and inflammatory factors. Our findings demonstrate the significant impact of dapagliflozin on the acceleration of blood flow recovery in a hindlimb ischemia mouse model, concomitant with a notable reduction in limb necrosis. Histological analysis revealed that dapagliflozin administration augmented the expression of key angiogenic markers, specifically CD31 and α-SMA, while concurrently mitigating muscle fibrosis. Furthermore, our investigation unveiled dapagliflozin’s ability to induce a phenotypic shift of macrophages from M1 to M2, thereby diminishing the expression of inflammatory factors, including IL-1β, IL-6, and TNF-α. These effects were partially mediated through modulation of the NF-κB signaling pathway. Lastly, we observed that endothelial cell proliferation, migration, and tube-forming function are enhanced in vitro by utilizing a macrophage-conditioned medium derived from dapagliflozin treatment. Taken together, our study provides evidence that dapagliflozin holds potential as an efficacious therapeutic intervention in managing CLI by stimulating angiogenesis, thereby offering a novel option for clinical CLI treatment.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2023) studied Critical limb ischemia. Dapagliflozin was evaluated on Recovery from limb ischemia (blood flow recovery, limb necrosis, angiogenic markers). Dapagliflozin accelerated blood flow recovery and reduced limb necrosis in a hindlimb ischemia mouse model by inducing M2 macrophage polarization and stimulating angiogenesis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: